TP53 and B-cell chronic lymphocytic leukemia: Reminiscent of the situation in human patients18, Trp53 deficiency was associated with the strongest reduction in median overall survival (31.4 weeks), compared to Atm deficiency (38.1 weeks) and animals that develop a TCL1-driven CLL on an Atm- and Trp53-proficient background (48.0 weeks; TCP vs. TC, p < 0.0001; TCP vs. TCA, p = 0.037; TCA vs. TC, p = 0.0003, log-rank test) (Fig. 1h).